1. von Magnus P, Andersen EK, Petersen KB, Birch-Andersen A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand 1959;46:156–176.
2. Arita I, Henderson DA. Smallpox and monkeypox in non-human primates. Bull World Health Organ 1968;39:277–283.
3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ 1972;46:593–597.
4. Lourie B, Bingham PG, Evans HH, Foster SO, Nakano JH, Herrmann KL. Human infection with monkeypox virus: laboratory investigation of six cases in West Africa. Bull World Health Organ 1972;46:633–639.
5. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis 2019;13(10):e0007791–e0007791.
6. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox — a potential threat? A systematic review. PLoS Negl Trop Dis 2022;16(2):e0010141–e0010141.
7. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004;350:342–350.
8. Mauldin MR, McCollum AM, Nakazawa YJ, et al. Exportation of monkeypox virus from the African Continent. J Infect Dis 2022;225:1367–1376.
9. Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis 2021;27:1007–1014.
10. Ogoina D, Izibewule JH, Ogunleye A, et al. The 2017 human monkeypox outbreak in Nigeria — report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS One 2019;14(4):e0214229–e0214229.
11. Yinka-Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis 2019;19:872–879.
12. Hobson G, Adamson J, Adler H, et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill 2021;26:2100745–2100745.
13. Rao AK, Schulte J, Chen T-H, et al. Monkeypox in a traveler returning from Nigeria — Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep 2022;71:509–516.
14. Antinori A, Mazzotta V, Vita S, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill 2022;27:2200421–2200421.
15. Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill 2022;27:2200424–2200424.
16. Vivancos R, Anderson C, Blomquist P, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill 2022;27:2200422–2200422.
17. Kluge H, Ammon A. Monkeypox in Europe and beyond — tackling a neglected disease together. Euro Surveill 2022;27:2200482–2200482.
18. Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields’ virology 5th ed. New York: Lippincott Williams and Wilkins, 2007:2905–2946.
19. Damon IK. Poxviruses. In: Knipe DM, Howley PM, eds. Fields’ virology 5th ed. New York: Lippincott Williams and Wilkins, 2007:2947–2976.
20. Cardeti G, Gruber CEM, Eleni C, et al. Fatal outbreak in tonkean macaques caused by possibly novel orthopoxvirus, Italy, January 2015. Emerg Infect Dis 2017;23:1941–1949.
21. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol 1988;17:643–650.
22. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010;107:16262–16267.
23. Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005;340:46–63.
24. Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005;86:2661–2672.
25. Happi C, Adetifa I, Mbala P, et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol 2022;20(8):e3001769–e3001769.
26. Doty JB, Malekani JM, Kalemba LN, et al. Assessing monkeypox virus prevalence in small mammals at the human-animal interface in the Democratic Republic of the Congo. Viruses 2017;9:283–283.
27. Khodakevich L, Jezek Z, Kinzanzka K. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet 1986;1:98–99.
28. Radonić A, Metzger S, Dabrowski PW, et al. Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg Infect Dis 2014;20:1009–1011.
29. Tiee MS, Harrigan RJ, Thomassen HA, Smith TB. Ghosts of infections past: using archival samples to understand a century of monkeypox virus prevalence among host communities across space and time. R Soc Open Sci 2018;5:171089–171089.
30. Reynolds MG, Doty JB, McCollum AM, Olson VA, Nakazawa Y. Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health. Expert Rev Anti Infect Ther 2019;17:129–139.
31. Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, Xiao SY. Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg Infect Dis 2004;10:1563–1567.
32. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis 1987;156:293–298.
33. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58:260–267.
34. Learned LA, Reynolds MG, Wassa DW, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005;73:428–434.
35. Doshi RH, Guagliardo SAJ, Doty JB, et al. Epidemiologic and ecologic investigations of monkeypox, Likouala department, Republic of the Congo, 2017. Emerg Infect Dis 2019;25:281–289.
36. Berthet N, Nakouné E, Whist E, et al. Maculopapular lesions in the Central African Republic. Lancet 2011;378:1354–1354.
37. Besombes C, Gonofio E, Konamna X, et al. Intrafamily transmission of monkeypox virus, Central African Republic, 2018. Emerg Infect Dis 2019;25:1602–1604.
38. Nakoune E, Lampaert E, Ndjapou SG, et al. A nosocomial outbreak of human monkeypox in the Central African Republic. Open Forum Infect Dis 2017;4:ofx168–ofx168.
39. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004;4:15–25.
40. Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005;41:1742–1751.
41. Petersen E, Kantele A, Koopmans M, et al. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am 2019;33:1027–1043.
42. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M, Grab B. Human monkeypox: confusion with chickenpox. Acta Trop 1988;45:297–307.
43. Hutin YJ, Williams RJ, Malfait P, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 2001;7:434–438.
44. Rimoin AW, Kisalu N, Kebela-Ilunga B, et al. Endemic human monkeypox, Democratic Republic of Congo, 2001–2004. Emerg Infect Dis 2007;13:934–937.
45. Hughes CM, Liu L, Davidson WB, et al. A tale of two viruses: coinfections of monkeypox and varicella zoster virus in the Democratic Republic of Congo. Am J Trop Med Hyg 2020;104:604–611.
46. Hoff NA, Doshi RH, Colwell B, et al. Evolution of a disease surveillance system: an increase in reporting of human monkeypox disease in the Democratic Republic of the Congo, 2001–2013. Int J Trop Dis Health 2017;25:IJTDH.35885–IJTDH.35885.
47. Doshi RH, Alfonso VH, Morier D, et al. Monkeypox rash severity and animal exposures in the Democratic Republic of the Congo. Ecohealth 2020;17:64–73.
48. Nolen LD, Osadebe L, Katomba J, et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg Infect Dis 2016;22:1014–1021.
49. Vandenbogaert M, Kwasiborski A, Gonofio E, et al. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic. Sci Rep 2022;12:10768–10768.
50. McMullen CL, Mulembekani P, Hoff NA, et al. Human monkeypox transmission dynamics thirty years after smallpox eradication in the Sankuru district, democratic republic of Congo. Am J Trop Med Hyg 2015;93:341–341.
51. Ferré VM, Bachelard A, Zaidi M, et al. Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. Ann Intern Med 2022 August 16 (Epub ahead of print).
52. Isidro J, Borges V, Pinto M, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med 2022;28:1569–1572.
53. Centers for Disease Control and Prevention. 2022 monkeypox outbreak global map. September 20, 2022 (https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html).
54. UK Health Security Agency. Investigation into monkeypox outbreak in England: technical briefing 2. September 2, 2022 (https://www.gov.uk/government/publications/monkeypox-outbreak-technical-briefings/investigation-into-monkeypox-outbreak-in-england-technical-briefing-2).
55. Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries — April–June 2022. N Engl J Med 2022;387:679–691.
56. Kugelman JR, Johnston SC, Mulembakani PM, et al. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerg Infect Dis 2014;20:232–239.
57. Patrocinio-Jesus R, Peruzzu F. Monkeypox genital lesions. N Engl J Med 2022;387:66–66.
58. Patel A, Bilinska J, Tam JCH, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ 2022;378:e072410–e072410.
59. Davido B, D’anglejan E, Jourdan J, Robinault A, Davido G. Monkeypox 2022 outbreak: cases with exclusive genital lesions. J Travel Med 2022;29:taac077–taac077.
60. Hammerschlag Y, MacLeod G, Papadakis G, et al. Monkeypox infection presenting as genital rash, Australia, May 2022. Euro Surveill 2022;27:2200411–2200411.
61. Tarín-Vicente EJ, Alemany A, Agud-Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet 2022;400:661–669.
62. Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health 2018;6:241–241.
63. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med 2018;379:44–53.
64. Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 2010;54:2560–2566.
65. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 2012;56:4900–4905.
66. Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22:1153–1162.
67. Chan-Tack K, Harrington P, Bensman T, et al. Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration’s Evaluation. Antiviral Res 2021;195:105182–105182.
68. Food and Drug Administration. Tembexa (brincidofovir): highlights of prescribing information. June 2021 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf).
69. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369:1227–1236.
70. Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the treatment of monkeypox — past, present, and future considerations. N Engl J Med 2022;387:579–581.
71. French National Agency for Research on AIDS. Monkeypox: CORE protocol for an international trial of the safety and efficacy of treatments. July 28, 2022 (https://www.anrs.fr/en/actualites/1127/monkeypox-core-protocol-international-trial-safety-and-efficacy-treatments).
72. Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 2006;10:193–201.
73. WHO Advisory Committee on Variola Virus Research. Report of the twenty-third meeting: virtual meeting, 3–4 November 2021. Geneva: World Health Organization, 2021 (https://apps.who.int/iris/rest/bitstreams/1423719/retrieve).
74. Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine 2021;39:5541–5547.
75. Malarkry M, Gruber M. Food and Drug Administration. Biological License Application approval letter for MVA-BN vaccine, Bavarian Nordic. Silver Spring, MD: Food and Drug Administration, September 24, 2019 (https://www.fda.gov/media/131079/download).
76. Eto A, Saito T, Yokote H, Kurane I, Kanatani Y. Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8. Vaccine 2015;33:6106–6111.
77. Le Guludec D. Avis n° 2022.0034/SESPEV du 20 mai 2022 du collège de la Haute Autorité de Santé relatif à la vaccination contre Monkeypox. Haute Autorité de Santé, May 20, 2022 (https://www.has-sante.fr/upload/docs/application/pdf/2022-05/avis_n2022.0034_sespev_du_20_mai_2022_du_college_de_la_has_relatif_a_la_vaccination_contre_la_variole_du_singe_monkeypox_vir.pdf).
78. UK Health Security Agency. Monkeypox: vaccine to be offered more widely to help control outbreak. June 21, 2022 (https://www.gov.uk/government/news/monkeypox-vaccine-to-be-offered-more-widely-to-help-control-outbreak).
